Bei Bei1, Lauren D Asarnow2, Andrew Krystal3, Jack D Edinger4, Daniel J Buysse5, Rachel Manber2. 1. Monash Institute of Cognitive and Clinical Neurosciences, School of Psychological Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University. 2. Department of Psychiatry and Behavioral Sciences, Stanford University. 3. School of Medicine, University of California, San Francisco. 4. Department of Medicine, National Jewish Health. 5. Department of Psychiatry, University of Pittsburgh.
Abstract
OBJECTIVE: Insomnia and major depressive disorders (MDD) often co-occur, and such comorbidity has been associated with poorer outcomes for both conditions. However, individual differences in depressive symptom trajectories during and after treatment are poorly understood in comorbid insomnia and depression. This study explored the heterogeneity in long-term depression change trajectories, and examined their correlates, particularly insomnia-related characteristics. METHOD:Participants were 148 adults (age M± SD = 46.6 ± 12.6, 73.0% female) with insomnia and MDD who receivedantidepressant pharmacotherapy, and were randomized to 7-session Cognitive Behavioral Therapy for Insomnia or control conditions over 16 weeks with 2-year follow-ups. Depression and insomnia severity were assessed at baseline, biweekly during treatment, and every 4 months thereafter. Sleep effort and beliefs about sleep were also assessed. RESULTS: Growth mixture modeling revealed three trajectories: (a) Partial-Responders (68.9%) had moderate symptom reduction during early treatment (p value < .001) and maintained mild depression during follow-ups. (b) Initial-Responders (17.6%) had marked symptom reduction during treatment (p values < .001) and low depression severity at posttreatment, but increased severity over follow-up (p value < .001). (c) Optimal-Responders (13.5%) achieved most gains during early treatment (p value < .001), continued to improve (p value < .01) and maintained minimal depression during follow-ups. The classes did not differ significantly on baseline measures or treatment received, but differed on insomnia-related measures after treatment began (p values < .05): Optimal-Responders consistently endorsed the lowest insomnia severity, sleep effort, and unhelpful beliefs about sleep. CONCLUSIONS: Three depression symptom trajectories were observed among patients with comorbid insomnia and MDD. These trajectories were associated with insomnia-related constructs after commencing treatment. Early changes in insomnia characteristics may predict long-term depression outcomes. (PsycINFO Database Record (c) 2018 APA, all rights reserved).
RCT Entities:
OBJECTIVE:Insomnia and major depressive disorders (MDD) often co-occur, and such comorbidity has been associated with poorer outcomes for both conditions. However, individual differences in depressive symptom trajectories during and after treatment are poorly understood in comorbid insomnia and depression. This study explored the heterogeneity in long-term depression change trajectories, and examined their correlates, particularly insomnia-related characteristics. METHOD:Participants were 148 adults (age M ± SD = 46.6 ± 12.6, 73.0% female) with insomnia and MDD who received antidepressant pharmacotherapy, and were randomized to 7-session Cognitive Behavioral Therapy for Insomnia or control conditions over 16 weeks with 2-year follow-ups. Depression and insomnia severity were assessed at baseline, biweekly during treatment, and every 4 months thereafter. Sleep effort and beliefs about sleep were also assessed. RESULTS: Growth mixture modeling revealed three trajectories: (a) Partial-Responders (68.9%) had moderate symptom reduction during early treatment (p value < .001) and maintained mild depression during follow-ups. (b) Initial-Responders (17.6%) had marked symptom reduction during treatment (p values < .001) and low depression severity at posttreatment, but increased severity over follow-up (p value < .001). (c) Optimal-Responders (13.5%) achieved most gains during early treatment (p value < .001), continued to improve (p value < .01) and maintained minimal depression during follow-ups. The classes did not differ significantly on baseline measures or treatment received, but differed on insomnia-related measures after treatment began (p values < .05): Optimal-Responders consistently endorsed the lowest insomnia severity, sleep effort, and unhelpful beliefs about sleep. CONCLUSIONS: Three depression symptom trajectories were observed among patients with comorbid insomnia and MDD. These trajectories were associated with insomnia-related constructs after commencing treatment. Early changes in insomnia characteristics may predict long-term depression outcomes. (PsycINFO Database Record (c) 2018 APA, all rights reserved).
Authors: Madhukar H Trivedi; A John Rush; Stephen R Wisniewski; Andrew A Nierenberg; Diane Warden; Louise Ritz; Grayson Norquist; Robert H Howland; Barry Lebowitz; Patrick J McGrath; Kathy Shores-Wilson; Melanie M Biggs; G K Balasubramani; Maurizio Fava Journal: Am J Psychiatry Date: 2006-01 Impact factor: 18.112
Authors: Colleen E Carney; Jack D Edinger; Charles M Morin; Rachel Manber; Bruce Rybarczyk; Edward J Stepanski; Helen Wright; Leon Lack Journal: J Psychosom Res Date: 2010-01 Impact factor: 3.006
Authors: Rachel Manber; Jack D Edinger; Jenna L Gress; Melanie G San Pedro-Salcedo; Tracy F Kuo; Tasha Kalista Journal: Sleep Date: 2008-04 Impact factor: 5.849
Authors: Stephen F Smagula; Robert M Boudreau; Katie Stone; Charles F Reynolds; Joyce T Bromberger; Sonia Ancoli-Israel; Thuy-Tien Dam; Elizabeth Barrett-Connor; Jane A Cauley Journal: Chronobiol Int Date: 2015-11-23 Impact factor: 2.877
Authors: Elaine M Boland; Jeffrey R Vittengl; Lee Anna Clark; Michael E Thase; Robin B Jarrett Journal: J Affect Disord Date: 2019-10-31 Impact factor: 4.839
Authors: Chanel Zhan; Gabriela A Nagy; Jade Q Wu; Brian McCabe; Allison M Stafford; Rosa M Gonzalez-Guarda Journal: J Immigr Minor Health Date: 2022-03-15
Authors: Alison E Carney; Delainey L Wescott; Nicole E Carmona; Colleen E Carney; Kathryn A Roecklein Journal: J Affect Disord Date: 2022-05-18 Impact factor: 6.533
Authors: Katherine E Miller; Christine M Ramsey; Elaine M Boland; Elizabeth A Klingaman; Philip Gehrman Journal: Sleep Date: 2021-07-09 Impact factor: 5.849
Authors: Stephane Borentain; David Williamson; Ibrahim Turkoz; Vanina Popova; William V McCall; Maju Mathews; Frank Wiegand Journal: Neuropsychiatr Dis Treat Date: 2021-11-30 Impact factor: 2.570
Authors: Bei Bei; Donna M Pinnington; Nina Quin; Lin Shen; Michelle Blumfield; Joshua F Wiley; Sean P A Drummond; Louise K Newman; Rachel Manber Journal: Psychol Med Date: 2021-07-07 Impact factor: 7.723